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Aim To investigate the genetic factors involved in the de-
velopment of non-alcoholic fatty liver disease (NAFLD) and 
its sequelae in a Middle Eastern population.
Methods This genetic case-control association study, con-
ducted in 2018, enrolled 30 patients with NAFLD and 30 
control individuals matched for age, sex, and body mass 
index. After quality control measures, entire exonic regions 
of 3654 genes associated with human diseases were se-
quenced. Allelic association test and enrichment analysis 
of the significant genetic variants were performed.
Results The association analysis was conducted on 27 
NAFLD patients and 28 controls. When Bonferroni cor-
rection was applied, NAFLD was significantly associ-
ated with rs2303861, a variant located in the CD82 gene 
(P = 2.49 × 10−7, adjusted P = 0.0059). When we used Ben-
jamini-Hochberg adjustment for correction, NAFLD was 
significantly associated with six more variants. Enrich-
ment analysis of the genes corresponding to all the seven 
variants showed significant enrichment for miR-193b-5p 
(P = 0.00004, adjusted P = 0.00922).
Conclusion A variant on CD82 gene and a miR-193b ex-
pression dysregulation may have a role in the develop-
ment and progression of NAFLD and its sequelae.
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Non-alcoholic fatty liver disease (NAFLD) is the most com-
mon liver disease in many parts of the world and an im-
portant global health concern (1-4). As a hepatic manifes-
tation of metabolic syndrome, it is closely associated with 
obesity, insulin resistance, and dyslipidemia (5). NAFLD 
prevalence is steadily on the rise due to a global increasing 
trend in obesity incidence (5,6) and within the next decade 
NAFLD is predicted to replace hepatitis C as the leading in-
dication for liver transplantation in the United States (1).
The main causes of mortality among patients with NAFLD 
are malignancies and cardiovascular diseases (7,8). The 
condition is an independent risk factor for hepatocellu-
lar carcinoma (HCC), which was previously thought to re-
quire liver cirrhosis as its precursor but has been recently 
described in patients with simple hepatic steatosis and no 
sign of inflammation or fibrosis (9,10). NAFLD is also close-
ly associated with an increased risk of colorectal cancer 
(11,12), as well as with myocardial remodeling, thus play-
ing an important role in the development of heart failure 
(13,14). The observed association between NAFLD, HCC, 
colorectal cancer, and heart failure implies that there is 
a possible underpinning defect in cellular processes that 
link cell metabolism to cell division and metabolite traf-
ficking.
The underlying risk factors for NAFLD (eg, obesity and 
diabetes mellitus) are associated with numerous genetic 
polymorphisms (15-17). Genetic factors could also in part 
explain the extreme variation in the worldwide NAFLD 
prevalence (6) and considerable inter-individual variabili-
ty in disease severity, morbidity, and mortality (18). NAFLD 
was found to be significantly associated with SNP rs738409 
(I148M) in PNPLA3 gene on chromosome 22, encoding an 
enzyme responsible for the hydrolysis of triacylglycerols 
in adipocytes; individuals homozygous for this allele had 
more than twice as much hepatic fat content as non-carri-
ers (19). Variants in other genes (eg, MBOAT7, TM6SF2, etc) 
(20), as well as dysregulated expression of several micro-
RNAs (miRNAs), were also found to contribute to NAFLD 
pathogenesis (21). For instance, miR-33a/b modulates the 
risk of metabolic syndrome by regulating various metabol-
ic pathways (22).
To the best of our knowledge, no genetic case-control as-
sociation study has so far been conducted on NAFLD in 
the Middle Eastern population, despite the fact that the 
underlying genetic factors of NAFLD and their relative 
contributions might differ from those in other popula-
tions. Therefore, after controlling for traditional risk 
factors, we investigated the underlying genetic factors in-




The study included 30 patients with NAFLD (17 female) 
and 30 healthy controls (17 female) matched for age, sex, 
and body mass index (BMI), who were randomly selected 
(with a random number generator) from participants of 
a cross-sectional population-based study previously con-
ducted in Shiraz (23). Briefly, the previous study had en-
rolled 542 adult unrelated participants randomly selected 
from the general population through a proportional clus-
ter random sampling. They had been interviewed to ob-
tain demographic information and physically examined by 
a medical doctor. Participants with alcohol consumption, 
participants serologically positive for hepatitis B or hepa-
titis C, and those identified through the interview to have 
hepatic steatosis due to other competing etiologies (eg, 
drugs, bariatric surgery, etc) had been excluded. NAFLD 
had been ultrasonographically diagnosed by an experi-
enced radiologist unaware of the patients’ clinical informa-
tion according to a validated protocol (24).
The current study included only patients with confirmed 
moderate-to-severe hepatic steatosis. The absence of he-
patic steatosis in the control group was also documented 
by ultrasonography.
This study was conducted in compliance with the Decla-
ration of Helsinki. Written informed consent was obtained 
from all study participants who had been assured that 
their data would be kept confidential. The study was ap-
proved by the Research Ethics Committee of Health Policy 
Research Center affiliated to Shiraz University of Medical 
Sciences Ethics Committee.
Clinical and laboratory evaluation
Weight, height, waist circumference, hip circumference, 
and blood pressure had been measured and BMI was cal-
culated (23). Fasting venous blood samples were obtained, 
serum was separated, and fasting glucose, aspartate amin-
otransferase (AST), alanine aminotransferase (ALT), triacyl-
glycerols, high-density lipoprotein cholesterol, low-densi-
ty lipoprotein cholesterol, hepatitis B surface antigen, and 
hepatitis C virus antibodies were measured with an auto-
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mated analyzer (CS-1200 Auto-Chemistry Analyzer, DIRUI 
Industrial Co, Changchun, China).
dnA preparation, genotyping, and quality control
Genomic DNA was extracted from EDTA-anticoagulated 
peripheral whole blood collected from each individual 
with QIAamp DNA isolation mini kit (QIAGEN, Hilden, Ger-
many) by salting out technique. The quality of isolated 
DNA specimens was assessed by QUBIT 3.0 fluorometer 
(Thermo Fisher Scientific, Waltham, MA, USA). The entire 
exonic regions of 3654 genes associated with human dis-
eases (inherited disease panel, Agilent Technologies, Santa 
Clara, CS, USA) were sequenced above 70 × coverage on 
an Illumina NextSeq 500 platform (Illumina, San Diego, CA, 
USA). A total of 54 100 variants located in genomic loci of 
these genes were identified. Target Enrichment for Illumina 
Multiplexed sequencing protocol (v. D0, November 2015) 
with SureSelectQXT (Agilent Technologies) was used for indi-
vidual library preparation and sample pooling. The follow-
ing quality control measures were performed in PLINK, v. 
1.07 (Free Software Foundation Inc., Boston, MA, USA) (25): 
single nucleotide polymorphisms (SNPs) with minor allele 
frequency of <0.05, those with significant deviation from 
the Hardy-Weinberg equilibrium (P < 10−5), and those gen-
otyped for less than half of the studied population were ex-
cluded from analysis. All samples were screened for known 
damaging variants in the ATP7B, HFE, and SERPINA1 genes 
corresponding to Wilson’s disease, hemochromatosis, and 
α1-antitrypsin deficiency, respectively. Samples with dam-
aging mutations were excluded from the study.
Statistical analysis
The normality of distribution of continuous variables was 
tested with the one-sample Kolmogorov-Smirnov test. The 
variables are presented as mean ± standard deviation. Sig-
nificance of differences between two groups was tested 
with the t test for independent samples. The analyses were 
conducted in IBM SPSS, version 20 (IBM, Armonk, NY, USA).
The association between SNP genotype and NAFLD was 
assessed with the allelic association test in PLINK, which is 
a simple χ2 test for association based on a 2 × 3 case-con-
trol genotype counts contingency table (25,26). The ob-
tained P values were adjusted with Bonferroni correction 
for multiple comparisons, with the level of significance set 
at P < 2.1 × 10−6. Manhattan plot was drawn in Haploview 
(27). Logistic regression analysis was performed in PLINK 
using an additive genetic model adjusting for age, sex, and 
BMI. Genotypes for SNPs with significant P values were re-
coded as 0, 1, or 2, according to the number of alterna-
tive alleles present. Multiple linear regression analysis, per-
formed in SPSS, assessed the effect of the SNP’s alternative 
alleles that were found significant in allelic association test 
on clinical and biochemical parameters after adjustment 
for age, sex, and BMI. False discovery rate for each associa-
tion was calculated with the Benjamini-Hochberg method 
(28). SNPs with a false discovery rate <0.05 were included 
in the enrichment analysis. Information about overlapping 
or nearest gene corresponding to the associated SNPs 
was obtained by an SNP annotation tool (29). Enrichment 
analysis was carried out with Enrichr on miRTarBase data-
base (30,31). Significantly enriched miRNAs were identified 
from the list of genes corresponding to the SNPs that were 
found to be significantly different between patients and 
controls with the Fisher exact test in Enrichr.
reSuLtS
After quality control, 55 individuals – 27 patients with NA-
FLD and 28 controls – and 23 732 SNPs were included in 
the association analysis. Patients with NAFLD had signifi-
cantly higher mean fasting blood glucose and serum ALT 
(P < 0.05) (Table 1). The groups did not differ in any other 
parameter.
When Bonferroni correction was applied, NAFLD was sig-
nificantly associated with rs2303861, located on CD82 
gene (Figure 1, Table 2). After adjusting for age, sex, and 
BMI, the alternative allele of ‘G’ was associated with a 9-fold 
increase in the risk of developing NAFLD compared with 
the wild type ‘A’ (odds ratio 9.07, 95% confidence interval 
1.92-42.81). When Benjamini-Hochberg method was ap-
plied, six more SNPs were found to have false discovery 
rates of <0.05 (Table 2), meaning that they were also asso-
ciated with NAFLD development.
Multiple linear regression analysis did not show any signifi-
cant association between the seven SNP alleles and clinical 
and biochemical parameters, taking into account the mul-
tiple statistical tests performed (Table 3). Enrichment anal-
ysis of the genes corresponding to the seven SNPs found 
in the association study showed significant enrichment for 
miR-193b-5p (P = 0.00004, adjusted P = 0.00922).
diSCuSSion
Our study showed a significant association between 
NAFLD and a variant located in CD82 gene, as well 
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as significant enrichment for miR-193b-5p, meaning that 
the identified genes had significantly more targets of miR-
193b-5p than expected.
One of the basic mechanisms leading to NAFLD develop-
ment and progression is insulin resistance. Therefore, it 
is not surprising that NAFLD patients in our study had a 
tABLe 1. Clinical and biochemical characteristics of cases and controls
Parameter, mean and standard deviation nAFLd group (n = 27) Control group (n = 28) P
Age (years)  52.2 (10.1)  51.0 (9.0) 0.638
Body mass index (kg/m2)  28.0 (5.3) 27.2 (5.1) 0.569
Fasting blood glucose (mg/dL) 109.6 (40.4)  90.4 (14.7) 0.026
Triacylglycerols (mg/dL) 159.8 (71.0) 158.29 (75.6) 0.940
Low-density lipoprotein cholesterol (mg/dL) 106.8 (35.6) 117.7 (27.3) 0.208
High-density lipoprotein cholesterol (mg/dL)  45.2 (8.5)  49.7 (11.0) 0.093
Aspartate aminotransferase (IU/L)  28.0 (12.1)  24.1 (13.6) 0.273
Alanine aminotransferase (IU/L)  34.0 (18.5)  20.2 (8.7) 0.001
Systolic blood pressure (mm Hg) 120.6 (16.8) 120.1 (22.1) 0.933
Diastolic blood pressure (mm Hg)  77.9 (8.1)  78.5 (8.2) 0.807
Waist circumference (cm)  96.2 (18.6)  95.0 (11.5) 0.763
Hip circumference (cm) 103.7 (18.9) 104.1 (8.5) 0.911
tABLe 2. Leading single nucleotide polymorphisms (SnPs) associated with non-alcoholic fatty liver disease (nAFLd) identified by the 
allelic association test. the adjusted odds ratio (or) and confidence interval (Ci) were obtained in logistic regression analysis with an 
additive genetic model adjusting for age, sex, and body mass index.









11 rs2303861 44618466 CD82 A/G 2.49 × 10−7 0.0059 0.0059 9.07 (1.92-42.81)
4 rs13116873 26362678 RBPJ C/G 2.12 × 10−6 0.0502 0.0181 13.91 (2.38-81.45)
2 rs4671501 63404754 WDPCP A/C 3.69 × 10−6 0.0875 0.0181 0.10 (0.02-0.58)
14 rs1742546 91417155 CCDC88C G/A 4.15 × 10−6 0.0984 0.0181 0.25 (0.10-0.61)
19 rs2075754 41871176 RPS19 T/C 4.39 × 10−6 0.1043 0.0181 4.96 (1.57-15.66)
10 rs3752752 71695444 CDH23 T/C 4.57 × 10−6 0.1085 0.0181 4.52 (1.71-11.92)
7 rs740949 148808972 EZH2 A/G 8.37 × 10−6 0.1987 0.0284 0.19 (0.06-0.57)
*False discovery rate obtained by Benjamini-Hochberg method.
FiGure 1. the Manhattan plot based on the data obtained from the allelic association test. the x-axis represents the chromosomal 
location of the studied single nucleotide polymorphisms (SnPs). the y-axis is –log10(P value). the solid horizontal line corresponds to 
the Bonferroni-adjusted significance threshold, a P value of 2.1 × 10−6.
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higher fasting blood glucose level and ALT, the liver en-
zyme most closely associated with NAFLD (32). Since the 
cases and controls were matched for BMI, the differences 
observed between them could mainly be attributed to the 
processes involved in NAFLD development rather than to 
obesity.
CD82, or KAI1, expression is decreased or abolished in 
various malignant tumors (33). CD82 protein was present 
in about one-third of colorectal cancer tissues compared 
with more than half of normal mucosal tissues (34). In ad-
dition, its expression was lower in hepatocellular malig-
nant cells compared with healthy tissue (35) and in HCC 
patients compared with patients with liver cirrhosis or 
hepatitis, or control individuals (35). Taking all this into 
account, our finding that a variant located in CD82 gene 
was significantly associated with NAFLD might explain 
the increased risk of several malignancies in patients 
with NAFLD. However, further functional studies are re-
quired to assess the effect of this variant on CD82 gene 
expression.
CD82 null mice demonstrated enhanced bone marrow ad-
ipogenic potential, evidenced by augmented differentia-
tion into adipocytes and enhanced expression of adipo-
cyte differentiation markers (36). Our findings suggest that 
a similar mechanism may also take place in hepatocytes, 
leading to hepatic steatosis observed in patients with NA-
FLD. Furthermore, rs2303861, found in this study to be as-
sociated with NAFLD, is in linkage disequilibrium with an-
other variant, rs7942159, located on PNPLA2 gene, which is 
known to be involved in fat mobilization in adipose tissue 
(37,38). This might explain the effects of rs2303861 poly-
morphism in CD82 observed in our study.
Expression of miR-193b is directly correlated with the se-
cretion of adiponectin (39), a secretory protein exclusively 
produced by adipocytes, which increases hepatic insulin 
sensitivity and is inversely correlated with the presence of 
NAFLD and body fat content (40,41). One study also report-
ed an inverse correlation between miR-193b-5p expres-
sion level and BMI, glucose levels, and insulin responses to 
a 75-g oral glucose tolerance test (42). miR-193b expres-
sion level was significantly lower in liver cancer exosome 
and whole tissue compared with control tissues (43). Fur-
thermore, miR-193b down-regulation was associated with 
metastasis and depth of invasion in patients with liver can-
cer (43). Down-regulation of miR-193b was also demon-
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In summary, decreased miR-193b expression and the pres-
ence of a variant in CD82 gene might result in insulin re-
sistance, dysregulation of adipokines, and an increase in 
hepatic fat content, which might all cause NAFLD and ac-
tivate biological pathways leading to HCC, colorectal can-
cer, and heart failure. Our findings link miRNA expression to 
higher risk of cancer and heart disease in NAFLD patients, 
thus opening avenues for the treatment of NAFLD compli-
cations using miRNA blockers and miRNA mimics.
The strength of this study is the homogeneity of the stud-
ied population, use of next generation sequencing tech-
nology instead of array-based techniques, and the focus 
on the genetic loci associated with human diseases. The 
random selection of the studied sample from a population-
based study can be considered an additional strength, as 
the studied individuals may be considered representative 
of the general population residing in our region.
On the other hand, the small number of participants might 
have decreased the statistical power of our study to detect 
a small effect size. Therefore, our findings require further 
replication studies in larger cohorts from other popula-
tions to corroborate their potential significance.
In conclusion, our study provides an insight into a possi-
ble association between decreased miR-193b expression 
and NAFLD development, and subsequent increased inci-
dence of colorectal cancer, HCC, and heart failure. The ex-
istence of such association could allow the use of this miR-
NA in NAFLD management as a therapeutic target, disease 
biomarker, or method for treatment response assessment. 
Further studies, preferably performed in an independent 
cohort, should validate the associations found in this study, 
as well as unravel the underlying biological mechanisms 
involved.
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